Merck & Company (CH:6MK)
NYSE:6MK
6MK Stock Chart & Stats
CHF96.58
CHF0.00(0.00%)
At close: 4:00 PM EST
CHF96.58
CHF0.00(0.00%)
Day’s Range― - ―
52-Week RangeCHF96.58 - CHF96.58
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
CHF236.10B
Enterprise ValueCHF337.01B
Total Cash (Recent Filing)CHF5.70B
Total Debt (Recent Filing)CHF49.12B
Price to Earnings (P/E)33.1
BetaN/A
Next Earnings
Aug 04, 2026EPS Estimate
1.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.56
Shares Outstanding2,469,824,500
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.81
Price to Book (P/B)5.01
Price to Sales (P/S)4.06
P/FCF Ratio21.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF109.10Price Target Upside12.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
EPS Forecast (FY)4.06
Revenue Forecast (FY)CHF52.75B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationConsistently high and growing free cash flow (~$14.1B TTM, +14%) provides durable funding for R&D, launches, dividends and buybacks. That cash conversion (FCF ≈79% of net income) underpins strategic flexibility and reduces reliance on external financing over the medium term.
High Margin StructureElevated gross and operating margins (historical gross ~72–76% and operating ~28%; guidance ~82% gross) reflect durable pricing power from branded products and manufacturing scale. These margins support sustained reinvestment in pipeline and resilient cash flow even with modest revenue growth.
Leading Oncology Franchise & PipelineKEYTRUDA’s continued commercial momentum ($8.0B, +8% YoY) combined with multiple priority reviews, approvals and an active launch slate provides durable revenue upside. The broad oncology pipeline and regulatory progress reinforce long-term franchise resilience and future product cadence.
Bears Say
Moderate LeverageDebt-to-equity near 1.07 indicates meaningful reliance on leverage versus peers. With sizable outstanding debt, large M&A or cyclical weak profits could strain credit metrics, limit flexibility for opportunistic investment, and increase interest expense sensitivity over the medium term.
Earnings Volatility From Large One-offsVery large acquisition-related and transaction charges (Cidara ~$9B; expected one-time Terns R&D ~$5.8B) create substantial GAAP volatility and complicate trend analysis. Such episodic hits can distort profitability, tax rates and credit metrics, making forward earnings visibility harder to rely on.
Product Demand & Clinical SetbacksSignificant product-specific headwinds (GARDASIL -22%, reimbursement impacts on OHTUVAYRE) plus an important clinical miss (LITESPARK-012) show commercial and pipeline execution risks. Persistent demand shifts or regulatory setbacks could pressure revenues and offset new-launch gains over several quarters.
Merck & Company News
6MK FAQ
What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest stock price was CHF96.58 and its highest was CHF96.58 in the past 12 months.
What is Merck & Company’s market cap?
Merck & Company’s market cap is CHF236.10B.
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s upcoming earnings report date is Aug 04, 2026 which is in 55 days.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Apr 30, 2026. The company reported -CHF1.023 earnings per share for the quarter, beating the consensus estimate of -CHF1.178 by CHF0.155.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company does not currently pay dividends.
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is 1.68.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,469,824,500 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of -CHF1.023 in its last earnings report, beating expectations of -CHF1.178. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Merck & Company?
Currently, no hedge funds are holding shares in CH:6MK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Merck & Company Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF109.10 (12.96% Upside)
CHF109.10 (12.96% Upside)
Blogger Sentiment
Bullish
CH:6MK Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Bullish
Bullish news 79%
Bearish news 22%
Bearish news 22%
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.23%
12-Months-Change
Fundamentals
Return on Equity
17.93%
Trailing 12-Months
Asset Growth
11.78%
Trailing 12-Months
Company Description
Merck & Company
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
6MK Company Deck
6MK Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call mixed strong commercial and pipeline execution with near-term financial and clinical headwinds. Merck reported solid Q1 revenue growth (+5% YoY; $16.3B), robust KEYTRUDA momentum (+8%, $8.0B), notable product and regulatory milestones (IDVYNSO approval, priority reviews for I-DXd and multiple WELIREG filings), accelerating new-product launches and AI partnerships, and raised/narrowed 2026 guidance. Offsetting these positives were a very large one-time $9B Cidara charge that drove a GAAP loss and distorted tax rate, an expected one-time R&D impact from the proposed Terns deal (~$5.8B), meaningful declines in GARDASIL (-22%), a failed LITESPARK-012 readout, and several near-term reimbursement/seasonality headwinds for specific products (ENFLONSIA, OHTUVAYRE). Overall the company emphasized long-term pipeline value and raised guidance despite near-term charges and select clinical setbacks.View all CH:6MK earnings summaries6MK Sales Breakdown
89.43% Pharmaceutical
9.77% Animal Health
0.79% Other
6MK Stock 12 Month Forecast
Average Price Target
CHF109.10
▲(12.96% Upside)
Technical Analysis
Options Prices
Currently, No data available
---